The breakthrough in cancer therapy was witness by the introduction of immunotherapeutic approaches.
Global Breast Cancer Antibodies Biomarkers & Clinical Trials Insight 2028 Report `Highlights:
- Global Breast Cancer Antibodies Market Opportunity: > USD 15 Billion
- Breast Cancer Antibodies Clinical Trials Insight: > 150 Drugs In Trials
- Breast Cancer Biomarkers Sourced During Clinical Trials
- Breast Cancer Biomarkers Insight By Antibodies Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Antibody
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report: https://www.kuickresearch.com/ccformF.php?t=1646994975
Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028 Report Highlights:
- Global Immune Checkpoint Inhibitors Market Opportunity: > USD 30 Billion
- Immune Checkpoint Inhibitors Clinical Trials Insight: CTLA-4, LAG3, PD-1/PD-L1, TIGIT Inhibitors
- Immune Checkpoint Inhibitors Clinical Trials Insight: > 300 Drugs In Trials
- Biomarkers sourced During clinical Trials
- Biomarkers Insight By Immune Checkpoint Inhibitors Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Immune Checkpoint Inhibitor Drug
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report:
https://www.kuickresearch.com/report-immune-checkpoint-inhibitors-biomarkers
The breakthrough in cancer therapy was witness by the introduction of immunotherapeutic approaches. The advent of immunotherapy particularly immune checkpoint inhibitors, bispecific antibodies, chimeric antigen receptor (CAR) T-cell therapy, and others have shown to significantly impro0ve the progression free survival and overall survival in patients with wide range of malignancies including melanoma, lung cancer, acute lymphoblastic leukemia, colorectal cancer, and others. Despite these successes, the majority of patients who qualify for immune therapy derive no benefit, as a result of primary or secondary resistance to therapy.
To predict which patients will respond positively to certain treatments and track their progress, researchers search for predictive and prognostic immuno-oncology biomarkers. Currently, only programmed death ligand-1 (PD-L1), mismatch repair, microsatellite instability, and tumor mutational burden are the validated biomarkers in the market because each is associated with FDA-approved therapies. As the field of cancer immunotherapy continues to develop, pathologists bear an important responsibility to lead and support studies that explore and validate novel biomarkers.
The rising pipeline of immunotherapy associated with the unmet need for development of biomarker has encouraged pharmaceutical companies to actively invest in this segment. The major key players in the market have also adopted strategic alliances to maintain their position in the global market. For instance in 2022, Synlab and OncoDNA have announced a partnership to provide oncologists with the high-quality, pan-cancer OncoDEEP biomarker test in Germany. The comprehensive test helps to predict patient responses to a wide range of approved and experimental cancer therapies, further expanding Synlab’s offering in personalized diagnostics and precision medicine in the field of oncology. In addition, DarwinHealth also announced Prelude Therapeutics employing its Biomarker Enrichment Strategies for Trial (BEST Platform) to elucidate novel biomarkers to guide translational trajectories for multiple oncology molecules including immune checkpoint inhibitors.
To date, more than 1000 clinical trials are ongoing in cancer immunotherapy biomarker market, thus suggesting positive future of the market in coming years. Emerging evidences also suggests that gut microbiota influences the clinical response to cancer immunotherapy. In a recent study, researchers have identified groups of gut bacteria associated with favorable and unfavorable response to a type of immunotherapy called immune checkpoint blockade. They also found that microbes exert the most influence on melanoma patient outcomes about one year after starting treatment. By providing insights into how and when bacteria influence immune responses, the findings could aid development of microbiome-based cancer therapies during the forecast period.
As per our report findings, the global immunotherapy biomarker market will witness exponential growth by 2028 by registering high CAGR rates. This is mainly attributed to the increase in adoption of novel immunotherapeutic approaches for the management of wide range of cancers. Further, rise in incidences of cancer and strong clinical pipeline of immunotherapeutic drugs will also drive the growth of market during forecast period. However, the high cost associated with the research and development of the products consequently increases the cost of the final product and associated treatment, which is a factor expected to hamper the growth of the immunotherapy biomarker market.
Our report provides in-depth analysis on the currently available biomarker across various stages of clinical trial. This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges that will determine the market’s future growth. The major companies mentioned in the report are Amgen, Roche, Pfizer, Gilead Sciences, GlaxoSmthKline, and others.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com